Previous 10 | Next 10 |
home / stock / tenx / tenx articles
Tenax Therapeutics Inc (NASDAQ:TENX) shares are trading lower by 64.3% to $5.08 Thursday morning after the company announced the pricing of a publi...
U.S. stocks traded mixed this morning, following the release of jobless claims data on Thursday. Following the market opening Thursday, the Dow tra...
Shares of The Walt Disney Company (NYSE: DIS) rose in today’s pre-market trading following the release of quarterly results. The company rep...
Tenax Therapeutics, Inc. (NASDAQ:TENX) shares are trading higher by over 10% in the premarket session on Wednesday. The stock gained 31% in ye...
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite falling around 50 points on Tuesday. The Dow traded up 0.11% to 38,42...
Shares of FMC Corporation (NYSE: FMC) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter r...
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling more than 50 points on Tuesday. The Dow traded up 0.19% to 38,45...
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 100 points on Tuesday. Following the market opening Tuesday, the...
Once granted, this patent will: provide U.S. intellectual property (IP) protection until December 2040, and may qualify for additional U.S. paten...
News, Short Squeeze, Breakout and More Instantly...
Tenax Therapeutics Inc. Company Name:
TENX Stock Symbol:
NASDAQ Market:
Tenax Therapeutics Inc. Website:
Currently Enrolling Patients in Phase 3 LEVEL Study with 24 Investigative Sites Initiated Secured Global Development and Commercial Rights to Levosimendan for Treatment of PH-HFpEF Expanded Intellectual Property Estate for Levosimendan with Issuance of New U.S. Patent ...
Broadens IP protection for oral (TNX-103), IV, and subcutaneous use of levosimendan, and its active metabolites (OR1896 and OR1855), in PH-HFpEF Provides U.S. intellectual property (IP) protection until December 2040, and may qualify for additional U.S. patent term extension (PTE) beyond ...